KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Retained Earnings: 2009-2024

Historic Retained Earnings for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$15.2 billion.

  • Teva Pharmaceutical Industries' Retained Earnings rose 4.77% to -$14.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.2 billion, marking a year-over-year increase of 4.77%. This contributed to the annual value of -$15.2 billion for FY2024, which is 12.11% down from last year.
  • Teva Pharmaceutical Industries' Retained Earnings amounted to -$15.2 billion in FY2024, which was down 12.11% from -$13.5 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Retained Earnings' 5-year high stood at -$2.4 billion during FY2020, with a 5-year trough of -$15.2 billion in FY2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Retained Earnings averaged around -$10.5 billion, with its median value being -$13.5 billion (2023).
  • Data for Teva Pharmaceutical Industries' Retained Earnings shows a maximum YoY plummeted of 376.89% (in 2023) over the last 5 years.
  • Teva Pharmaceutical Industries' Retained Earnings (Yearly) stood at -$2.4 billion in 2020, then fell by 11.84% to -$2.7 billion in 2021, then declined by 5.78% to -$2.8 billion in 2022, then tumbled by 376.89% to -$13.5 billion in 2023, then declined by 12.11% to -$15.2 billion in 2024.